Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis

Stephen J. Forest, Rongbing Xie, James K. Kirklin, Jennifer Cowger, Yu Xia, Anne I. Dipchand, Cumara Sivathasan, Chris Merry, Lars H. Lund, Robert Kormos, Margaret M. Hannan, Takeshi Nakatani, Ulrich Jorde, Daniel J. Goldstein

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.

Original languageEnglish (US)
Pages (from-to)1207-1217
Number of pages11
JournalJournal of Heart and Lung Transplantation
Volume37
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Heart-Assist Devices
Registries
Body Mass Index
Equipment and Supplies
Infection
Morbidity
Thinness
Neurologic Manifestations
Hemorrhage
Transplants
Survival
Mortality

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Impact of body mass index on adverse events after implantation of left ventricular assist devices : An IMACS registry analysis. / Forest, Stephen J.; Xie, Rongbing; Kirklin, James K.; Cowger, Jennifer; Xia, Yu; Dipchand, Anne I.; Sivathasan, Cumara; Merry, Chris; Lund, Lars H.; Kormos, Robert; Hannan, Margaret M.; Nakatani, Takeshi; Jorde, Ulrich; Goldstein, Daniel J.

In: Journal of Heart and Lung Transplantation, Vol. 37, No. 10, 01.10.2018, p. 1207-1217.

Research output: Contribution to journalArticle

Forest, SJ, Xie, R, Kirklin, JK, Cowger, J, Xia, Y, Dipchand, AI, Sivathasan, C, Merry, C, Lund, LH, Kormos, R, Hannan, MM, Nakatani, T, Jorde, U & Goldstein, DJ 2018, 'Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis', Journal of Heart and Lung Transplantation, vol. 37, no. 10, pp. 1207-1217. https://doi.org/10.1016/j.healun.2018.06.004
Forest, Stephen J. ; Xie, Rongbing ; Kirklin, James K. ; Cowger, Jennifer ; Xia, Yu ; Dipchand, Anne I. ; Sivathasan, Cumara ; Merry, Chris ; Lund, Lars H. ; Kormos, Robert ; Hannan, Margaret M. ; Nakatani, Takeshi ; Jorde, Ulrich ; Goldstein, Daniel J. / Impact of body mass index on adverse events after implantation of left ventricular assist devices : An IMACS registry analysis. In: Journal of Heart and Lung Transplantation. 2018 ; Vol. 37, No. 10. pp. 1207-1217.
@article{54b7fb802a794a43a872fc9717ede04b,
title = "Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis",
abstract = "BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4{\%}) UW, 5,719 (61{\%}) NO, 2,770 (29{\%}) OB, and 444 (5{\%}) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8{\%} to 75.8{\%}, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3{\%}, 70.7{\%}) when compared with OB (58.3{\%}, 78.7{\%}), NO (65.2{\%}, 81.4{\%}), and UW (68.9{\%}, 77.4{\%}) patients. UW (81.5{\%}) and NO (81.3{\%}) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3{\%}) and MO (72.6{\%}) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.",
author = "Forest, {Stephen J.} and Rongbing Xie and Kirklin, {James K.} and Jennifer Cowger and Yu Xia and Dipchand, {Anne I.} and Cumara Sivathasan and Chris Merry and Lund, {Lars H.} and Robert Kormos and Hannan, {Margaret M.} and Takeshi Nakatani and Ulrich Jorde and Goldstein, {Daniel J.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.healun.2018.06.004",
language = "English (US)",
volume = "37",
pages = "1207--1217",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Impact of body mass index on adverse events after implantation of left ventricular assist devices

T2 - An IMACS registry analysis

AU - Forest, Stephen J.

AU - Xie, Rongbing

AU - Kirklin, James K.

AU - Cowger, Jennifer

AU - Xia, Yu

AU - Dipchand, Anne I.

AU - Sivathasan, Cumara

AU - Merry, Chris

AU - Lund, Lars H.

AU - Kormos, Robert

AU - Hannan, Margaret M.

AU - Nakatani, Takeshi

AU - Jorde, Ulrich

AU - Goldstein, Daniel J.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.

AB - BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.

UR - http://www.scopus.com/inward/record.url?scp=85053030246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053030246&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2018.06.004

DO - 10.1016/j.healun.2018.06.004

M3 - Article

C2 - 30195832

AN - SCOPUS:85053030246

VL - 37

SP - 1207

EP - 1217

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 10

ER -